Aerocrine

Pressrelease October 31, 2012

Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in "lagen (1991:980) om handel med finansiella instrument" it's hereby announced that through the subscription by exercise of options in Aerocrine the number of shares and votes in Aerocrine has increased during August 2012 as specified in the table below.

	Number of shares and votes
August 1, 2012	144 947 999
Increase	299 510
August 31, 2012	145 247 509

Solna October 31, 2012 Aerocrine AB (publ.)

For further information, please contact:

Michael Colérus, CFO, +46 8 629 07 85

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO[®] and NIOX[®] Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on October 31, 2012.